Welcome to our dedicated page for Mannkind SEC filings (Ticker: MNKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how MannKind finances the next generation of inhaled therapies can be daunting. Annual reports discuss Technosphere manufacturing, 8-K filings announce licensing deals, and clinical trial costs hide in dense footnotes. If you’ve ever typed “MannKind SEC filings explained simply” or wondered whether understanding MannKind SEC documents with AI is possible, you’re not alone. We begin by untangling the pages so you can focus on decisions, not deciphering.
Our platform delivers every MannKind quarterly earnings report 10-Q filing within minutes of EDGAR release, then produces a concise MannKind earnings report filing analysis that surfaces revenue from Afrezza, pipeline R&D spend, and cash runway changes. The same AI engine turns the MannKind annual report 10-K simplified into clear sections, and keeps MannKind 8-K material events explained in plain language, whether it’s a new distribution agreement or an FDA update.
Need insider visibility? Receive MannKind Form 4 insider transactions real-time alerts and scan historical MannKind insider trading Form 4 transactions to spot buying or selling before the market reacts. The feed also details every MannKind executive stock transactions Form 4 alongside governance data pulled from the MannKind proxy statement executive compensation tables. With AI-powered summaries, real-time updates, and coverage of all forms—from S-3 shelf registrations to definitive proxies—you'll find the right data in seconds.
Dominic Marasco, President of the Endocrine Business Unit at Mannkind, received a significant performance-based equity award on June 23, 2025. The insider was granted 1,000,000 performance restricted stock units (PRSUs) that represent the right to receive an equivalent number of common stock shares.
Key terms of the PRSU grant:
- Vesting date set for March 15, 2028
- Final payout ranges from 0% to 200% of target shares based on net sales performance
- Target amount is 1,000,000 shares, meaning maximum potential payout is 2,000,000 shares
- Exercise price of $0, making this a full-value award
This significant equity grant aligns the executive's interests with long-term company performance, specifically tied to net sales targets over an approximately 3-year performance period.
FAQ
What is the current stock price of Mannkind (MNKD)?
What is the market cap of Mannkind (MNKD)?
What is the primary focus of MannKind Corporation?
What technologies underpin MannKind's product portfolio?
How does MannKind differentiate its insulin product from traditional treatments?
What therapeutic areas does MannKind target?
How does MannKind integrate strategic partnerships in its business model?
What role does clinical research play at MannKind?
How does MannKind maintain its competitive advantage?
What are the key benefits of MannKind's inhaled drug delivery system?
